OLFML2B Is a Robust Prognostic Biomarker in Bladder Cancer Through Genome-Wide Screening: A Study Based on Seven Cohorts

BackgroundBladder cancer lacks useful and robust prognostic markers to stratify patients at risk. Our study is to identify a robust prognostic marker for bladder cancer.MethodsThe transcriptome and clinical data of bladder cancer were downloaded from multiple databases. We searched for genes with ro...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jiaxing Lin, Xiao Xu, Tianren Li, Jihang Yao, Meng Yu, Yuyan Zhu, Dan Sun
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	bladder cancer Kaplan-Meier macrophage marker prognosis Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/4fe6067f241f4b4e80ca4e57ea018ddf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4fe6067f241f4b4e80ca4e57ea018ddf
record_format	dspace
spelling	oai:doaj.org-article:4fe6067f241f4b4e80ca4e57ea018ddf2021-11-15T05:38:38ZOLFML2B Is a Robust Prognostic Biomarker in Bladder Cancer Through Genome-Wide Screening: A Study Based on Seven Cohorts2234-943X10.3389/fonc.2021.650678https://doaj.org/article/4fe6067f241f4b4e80ca4e57ea018ddf2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.650678/fullhttps://doaj.org/toc/2234-943XBackgroundBladder cancer lacks useful and robust prognostic markers to stratify patients at risk. Our study is to identify a robust prognostic marker for bladder cancer.MethodsThe transcriptome and clinical data of bladder cancer were downloaded from multiple databases. We searched for genes with robust prognosis by Kaplan-Meier analysis of the whole genome. CIBERSORT and TIMER algorithm was used to calculate the degree of immune cell infiltration.ResultsWe identified OLFML2B as a robust prognostic marker for bladder cancer in five cohorts. Kaplan-Meier analysis showed that patients with a high level of OLFML2B expression had a poor prognosis. The expression of OLFML2B increased with the increase of stage and grade. We found that patients with high expression of OLFML2B still had a poor prognosis in two small bladder cancer cohorts. OLFML2B also has the prognostic ability in ten other tumors, and the prognosis is poor in high expression. The correlation analysis between OLFML2B and immune cells showed that it was positively correlated with the degree of macrophage infiltration and highly co-expressed with tumor-associated macrophage markers. Finally, the Wound-healing assay and Colony formation assay results showed that the migration and proliferation ability of bladder cancer cell lines decreased after the knockdown of OLFML2B.ConclusionsIn summary, OLFML2B is a robust risk prognostic marker, and it can help patients with bladder cancer improve individualized treatment.Jiaxing LinXiao XuTianren LiJihang YaoMeng YuYuyan ZhuDan SunFrontiers Media S.A.articlebladder cancerKaplan-MeiermacrophagemarkerprognosisNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	bladder cancer Kaplan-Meier macrophage marker prognosis Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	bladder cancer Kaplan-Meier macrophage marker prognosis Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Jiaxing Lin Xiao Xu Tianren Li Jihang Yao Meng Yu Yuyan Zhu Dan Sun OLFML2B Is a Robust Prognostic Biomarker in Bladder Cancer Through Genome-Wide Screening: A Study Based on Seven Cohorts
description	BackgroundBladder cancer lacks useful and robust prognostic markers to stratify patients at risk. Our study is to identify a robust prognostic marker for bladder cancer.MethodsThe transcriptome and clinical data of bladder cancer were downloaded from multiple databases. We searched for genes with robust prognosis by Kaplan-Meier analysis of the whole genome. CIBERSORT and TIMER algorithm was used to calculate the degree of immune cell infiltration.ResultsWe identified OLFML2B as a robust prognostic marker for bladder cancer in five cohorts. Kaplan-Meier analysis showed that patients with a high level of OLFML2B expression had a poor prognosis. The expression of OLFML2B increased with the increase of stage and grade. We found that patients with high expression of OLFML2B still had a poor prognosis in two small bladder cancer cohorts. OLFML2B also has the prognostic ability in ten other tumors, and the prognosis is poor in high expression. The correlation analysis between OLFML2B and immune cells showed that it was positively correlated with the degree of macrophage infiltration and highly co-expressed with tumor-associated macrophage markers. Finally, the Wound-healing assay and Colony formation assay results showed that the migration and proliferation ability of bladder cancer cell lines decreased after the knockdown of OLFML2B.ConclusionsIn summary, OLFML2B is a robust risk prognostic marker, and it can help patients with bladder cancer improve individualized treatment.
format	article
author	Jiaxing Lin Xiao Xu Tianren Li Jihang Yao Meng Yu Yuyan Zhu Dan Sun
author_facet	Jiaxing Lin Xiao Xu Tianren Li Jihang Yao Meng Yu Yuyan Zhu Dan Sun
author_sort	Jiaxing Lin
title	OLFML2B Is a Robust Prognostic Biomarker in Bladder Cancer Through Genome-Wide Screening: A Study Based on Seven Cohorts
title_short	OLFML2B Is a Robust Prognostic Biomarker in Bladder Cancer Through Genome-Wide Screening: A Study Based on Seven Cohorts
title_full	OLFML2B Is a Robust Prognostic Biomarker in Bladder Cancer Through Genome-Wide Screening: A Study Based on Seven Cohorts
title_fullStr	OLFML2B Is a Robust Prognostic Biomarker in Bladder Cancer Through Genome-Wide Screening: A Study Based on Seven Cohorts
title_full_unstemmed	OLFML2B Is a Robust Prognostic Biomarker in Bladder Cancer Through Genome-Wide Screening: A Study Based on Seven Cohorts
title_sort	olfml2b is a robust prognostic biomarker in bladder cancer through genome-wide screening: a study based on seven cohorts
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/4fe6067f241f4b4e80ca4e57ea018ddf
work_keys_str_mv	AT jiaxinglin olfml2bisarobustprognosticbiomarkerinbladdercancerthroughgenomewidescreeningastudybasedonsevencohorts AT xiaoxu olfml2bisarobustprognosticbiomarkerinbladdercancerthroughgenomewidescreeningastudybasedonsevencohorts AT tianrenli olfml2bisarobustprognosticbiomarkerinbladdercancerthroughgenomewidescreeningastudybasedonsevencohorts AT jihangyao olfml2bisarobustprognosticbiomarkerinbladdercancerthroughgenomewidescreeningastudybasedonsevencohorts AT mengyu olfml2bisarobustprognosticbiomarkerinbladdercancerthroughgenomewidescreeningastudybasedonsevencohorts AT yuyanzhu olfml2bisarobustprognosticbiomarkerinbladdercancerthroughgenomewidescreeningastudybasedonsevencohorts AT dansun olfml2bisarobustprognosticbiomarkerinbladdercancerthroughgenomewidescreeningastudybasedonsevencohorts
_version_	1718428551706836992

OLFML2B Is a Robust Prognostic Biomarker in Bladder Cancer Through Genome-Wide Screening: A Study Based on Seven Cohorts

Ejemplares similares